Signaling via ErbB2 and ErbB3 Associates with Resistance and <i>Epidermal Growth Factor Receptor</i> (<i>EGFR</i>) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Kaisa Erjala(Palmetto Hematology Oncology), Klaus Elenius(Åbo Akademi University)
Clinical Cancer Research
July 1, 2006
Cited by 265


Related Papers